Prehab before transplant: could exercise and diet boost recovery?
NCT ID NCT07341698
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a program of resistance training and nutritional counseling, started before a stem cell transplant, can improve quality of life for blood cancer patients. 110 adults scheduled for a transplant will be randomly assigned to either the prehabilitation program or usual care. The main goal is to see if the program leads to better overall well-being.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- resistance training and nutritional counseling
- What this could lead to
- If it works, this could show that a structured pre-transplant exercise and nutrition program improves quality of life and recovery for blood cancer patients.
- What could go wrong
- This is an early full-scale trial, so results may not be definitive. The benefits of prehabilitation are still unproven, and individual results may vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 110 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Oct 2032
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Adult patients \>18 years will be eligible for inclusion if they are scheduled for a allo-HSCT with at least four weeks before their scheduled transplantation date. Exclusion Criteria: * pregnancy * physical or mental disabilities precluding test of muscle function * inability to read and understand Danish or English
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Allogeneic hematopoietic stem cell transplantation recipient are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Copenhagen University Hospital - Rigshospitalet
RECRUITINGCopenhagen, Denmark, 2100, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Vitamin a boost before stem cell transplant may shield the gut
- Could gratitude exercises aid blood cancer recovery?
- Can donor immune cells be engineered to fight blood cancer?
- 10,000 DNA samples could reveal hidden genetic triggers for leukemia and lymphoma
- New chemo cocktail aims to boost stem cell transplant success in leukemia
- Time-Restricted eating may beat cancer fatigue, new study hopes